Open Orphan PLC (AIM:ORPH, OTC:OPORF) (AIM: ORPH) f Yamin 'Mo' Khan, Chief Executive Officer, talks to Proactive London about being awarded a £5mln human challenge study contract by a European company to test an intravenous antiviral candidate for respiratory syncytial virus (RSV).
The biotech, an existing customer, will use the hVIVO RSV Human Challenge Study Model on a cohort of healthy young adult volunteers.
Revenues from the contract should be recognised across 2022 and 2023, said Open Orphan, with volunteers to be recruited through its volunteer recruitment arm, FluCamp.